Tom Scanlan, Ph.D., in his lab at Oregon Health & Science University. A company first founded in Scanlan’s OHSU lab, Autobahn Therapeutics, has attracted a $100 million investment to develop new treatments for major depressive disorder and bipolar depression, aiming to address the clinical need for better treatments for these conditions affecting millions of people. (OHSU/Christine Torres Hicks)
